Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study
, Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective..
, et al, Biosci. Rep., doi:10.1042/BSR20203455
Retrospective 258 hospitalized patients in Italy showing lower mortality with HCQ treatment, unadjusted relative risk RR 0.455, p<0.001. Data is in the supplementary appendix.
This study is excluded in the after exclusion results of meta
unadjusted results with no group details.
risk of death, 54.5% lower, RR 0.45, p < 0.001, treatment 41 of 202 (20.3%), control 25 of 56 (44.6%), NNT 4.1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Boari et al., 17 Nov 2020, retrospective, Italy, peer-reviewed, 20 authors.
Abstract: Bioscience Reports (2020) 40 BSR20203455
Prognostic factors and predictors of outcome in
patients with COVID-19 and related pneumonia: a
retrospective cohort study
of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy; 2 Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
Correspondence: Damiano Rizzoni (email@example.com)
The aim of the present study was to simultaneously assess several potential predictors of
outcome (co-morbidity, previous and in-hospital treatment, radiologic Brixia score) in patients with COVID-19.
This retrospective cohort study included 258 consecutive patients with confirmed COVID-19
admitted to a medical ward at Montichiari Hospital, Brescia, Italy from February 28th to April
30rd, 2020. Patients had SARS-CoV-2 related pneumonia with respiratory failure, and were
treated with hydroxychloroquine and lopinavir plus ritonavir. In some patients, additional
treatment with tocilizumab, dexamethasone and enoxaparin was adopted. Outcomes (death
or recovery) were assessed at the end of the discharge period or at the end of the follow-up
During hospitalization, 59 patients died, while 6 died after discharge. The following variables
were demonstrated to be associated with a worse prognosis: Radiologic Brixia score higher
than 8, presence at baseline of hypertension, diabetes, chronic obstructive pulmonary disease, heart disease, cancer, previous treatment with ACE-inhibitors or anti-platelet drugs.
Anticoagulant treatment during hospital admission with enoxaparin at a dose higher than
4000 U once daily was associated with a better prognosis.
In conclusion, our study demonstrates that some co-morbidities and cardiovascular risk
factors may affect prognosis. The radiologic Brixia score may be a useful tool to stratify the
risk of death at baseline. Anticoagulant treatment with enoxaparin might be associated to a
clinical benefit in terms of survival in patients with COVID-19.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.